Zavzpret is administered as a nasal spray [1].
What is Zavzpret used to treat?
Zavzpret is used for the acute treatment of migraine with or without aura in adults [1].
When was Zavzpret approved?
The U.S. Food and Drug Administration (FDA) approved Zavzpret on June 16, 2023 [1].
How does Zavzpret work?
Zavzpret contains the active ingredient zavegepant, which is a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the action of CGRP, a molecule implicated in migraine pain and other symptoms [1].
How is Zavzpret different from other migraine treatments?
Unlike oral medications, Zavzpret's nasal spray formulation allows for rapid absorption and quick relief of migraine symptoms [1]. This can be advantageous for individuals who experience nausea or vomiting during a migraine, which can hinder the effectiveness of oral drugs.
What is the recommended dosage for Zavzpret?
The recommended dose of Zavzpret is 10 mg, administered as one nasal spray in one nostril [1].
What are the potential side effects of Zavzpret?
Common side effects reported with Zavzpret include taste disturbances and nasal discomfort [1].
Are there any safety concerns with Zavzpret?
Zavzpret is not recommended for patients with a history of hypersensitivity to zavegepant [1].
What is the patent status for Zavzpret?
Information regarding the specific patent exclusivity for Zavzpret can be found on DrugPatentWatch.com [2].
Who manufactures Zavzpret?
Zavzpret is manufactured by Pfizer [1].
---
Sources
[1] U.S. Food and Drug Administration. (2023, June 16). FDA approves Zavzpret (zavegepant) nasal spray for the acute treatment of migraine. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-zavzpret-zavegepant-nasal-spray-acute-treatment-migraine
[2] DrugPatentWatch.com. Retrieved from https://www.drugpatentwatch.com/